Coronavirus Notebook: EMA Begins Rolling Review of Sinovac Vaccine, Looks At Comirnaty In 12-15-Year Age Group
Executive Summary
Moderna and Sweden are donating vaccines to the COVAX Facility, and an African trial is investigating a combination of nitazoxanide and ciclesonide in people with mild-to-moderate COVID-19.
You may also be interested in...
Coronavirus Notebook: EMA Hones In On COVID-19 Activities, Russia’s Sputnik V Launches In India
A new study shows that the immune response to Pfizer/BioNTech’s Comirnaty in elderly people is 3.5-fold greater when the second dose is given after 12 weeks rather than three. The WHO has OKd the emergency use of a Chinese vaccine.
Coronavirus Update: Moderna Donates More Doses, Booster Shot Shows Efficacy
Novavax said it would start shipping supplies of its vaccine to Europe starting in late 2021, while Vaxart delayed the start of its Phase II study due to issues with Emergent BioSolutions. Meanwhile, Roche India received an EUA for Regeneron's antibody cocktail
Emergent COVID-19 Vaccine Plant’s Quality Issues Draw Unusual Spotlight From US FDA Topsiders
Remediation must be quick and sure, say FDA’s Woodcock and Marks, despite challenges with facilities, equipment, processes and personnel training.